MetaCap

Coya Therapeutics (COYA) vs Gossamer Bio (GOSS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Coya Therapeutics (COYA) has outperformed Gossamer Bio (GOSS) over the past year, losing 50.7% versus a loss of 95.6%. Coya Therapeutics is the larger company by market cap ($69.2 million vs $65.6 million), about 1.1 times the size. Coya Therapeutics converts more of its revenue into profit, with a net margin of -267.1% versus -351.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COYA-50.67%GOSS-95.62%
+30%-36%-103%
Nov 21, 20251 yearNov 20, 2026
COYA-37.74%GOSS-93.82%
+124%+9%-105%
Dec 26, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COYA versus GOSS key metrics
MetricCOYAGOSS
Share price$2.95$10.72
Market cap$69.20M$65.57M
1-day change-1.01%-4.54%
YTD return-49.14%-95.68%
1-year return-50.67%-95.62%
5-year return—-98.74%
EPS (TTM)$-1.39$-42.41
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$7.95M$48.47M
Revenue growth (YoY)+123.57%-57.74%
Net income (latest FY)$-21.23M$-170.37M
Operating margin-283.87%-352.23%
Net margin-267.14%-351.49%
52-week high$6.62$309.60
52-week low$2.72$8.29
Distance from 52-week high-55.44%-96.54%
Analyst consensusstrong_buybuy
Avg. price target upside+415.59%+669.40%
Average volume149.18K243.40K
Shares outstanding23.46M6.12M
Employees8161
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • COYA has outperformed GOSS by 45.0 percentage points over the past year.
  • Coya Therapeutics is more profitable, keeping -267.1 cents of every revenue dollar as net income versus -351.5 cents for Gossamer Bio.
  • Coya Therapeutics grew revenue faster in its latest fiscal year (+123.57% vs -57.74%).

About Coya Therapeutics

COYA stock →

Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Gossamer Bio

GOSS stock →

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.

Health Care · Biotechnology: Pharmaceutical Preparations · 161 employees

COYA vs GOSS FAQ

Which is bigger, Coya Therapeutics or Gossamer Bio?

Coya Therapeutics (COYA) is larger, with a market capitalization of $69.20M compared with $65.57M for Gossamer Bio (GOSS).

Which stock has performed better over the past year, COYA or GOSS?

COYA returned -50.67% over the past 12 months, compared with -95.62% for GOSS (price return, excluding dividends). Past performance does not predict future results.

Are Coya Therapeutics and Gossamer Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons